男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影

AstraZeneca to build $200m center in China

Updated: 2011-10-12 09:56

By Ma Zhenhuan (China Daily)

  Comments() Print Mail Large Medium  Small 分享按鈕 0

AstraZeneca to build $200m center in China

AstraZeneca PLC workers load blister strips onto a packing line at a factory in Macclesfield, United Kingdom. The UK-based medical company will create 600 jobs by building a new factory in Taizhou, Jiangsu province. [Photo / Bloomberg]

SHANGHAI - AstraZeneca PLC, one of the world's leading pharmaceutical companies, said it would invest $200 million to launch a new manufacturing facility in China to meet growing demand, including in rural areas.

Construction work on the project, in the China Medical City in Taizhou of East China's Jiangsu province, is scheduled for completion by the end of 2013, creating approximately 600 jobs.

This will be London-based AstraZeneca's largest single investment in a manufacturing facility globally. The new plant will produce intravenous and oral solid products, the company said.

"The new facility will significantly enhance our capacity and allow us to meet the growing healthcare demand of the Chinese population, and help us expand into the 900 million (rural) people outside of the big cities and hospitals," Mark Mallon, president of AstraZeneca China, told China Daily in an exclusive interview on Monday.

"It will also allow us to free up some capacity at our existing manufacturing facility in Wuxi, Jiangsu, to bring on more new innovative products that will be launched over the next few years," he added.

The Chinese pharmaceutical market grew from $10 billion in 2004 to $41 billion in 2010, according to market research agency IMS Health Inc, and it is expected to reach $102 billion by 2015.

Mallon said that he believes the Chinese government's focus on healthcare reform and investment in improving healthcare infrastructure and expanding insurance coverage will continue to drive the company's business growth and increase access to quality medicines over the longer term.

AstraZeneca will launch two new products, Faslodex, a treatment for breast cancer, and Onglyza, a new treatment for Type-2 Diabetes, in China this year.

Mallon also mentioned that the company is planning to launch Brilinta, an oral antiplatelet treatment for acute coronary syndrome, next year in China.

With an enhanced manufacturing capacity and the launch of more innovative new medicines, the company is planning to produce more affordable medicines for Chinese patients. It will adopt a multi-channel approach to sell its products to markets beyond big cities and hospitals.

Aside from the medical sales representatives who deal with individual physicians in big cities, the company has developed a team of about 100 customer service representatives who organize educational programs for small clinics and community health centers in China's rural areas.

It will also set up an inbound and outbound call center to reach out to healthcare professionals through phone calls, helping them learn more about AstraZeneca products, he said.

The company, which entered China in 1993, has invested about $500 million in the country, including an innovation center in Zhangjiang, Shanghai.

主站蜘蛛池模板: 汉川市| 桑植县| 东乌珠穆沁旗| 乌兰县| 东丽区| 沭阳县| 神池县| 南丰县| 嵊泗县| 轮台县| 定襄县| 新化县| 扎鲁特旗| 毕节市| 台安县| 卓资县| 樟树市| 金乡县| 曲松县| 平罗县| 呈贡县| 民乐县| 昭苏县| 南岸区| 建德市| 子长县| 锦屏县| 吴川市| 颍上县| 德格县| 交口县| 泰兴市| 平武县| 吉隆县| 陕西省| 银川市| 遵化市| 富顺县| 乡宁县| 商洛市| 徐闻县| 安阳县| 雷山县| 鹿邑县| 蓝山县| 呼图壁县| 林芝县| 涞水县| 洮南市| 卓资县| 凌源市| 台南县| 尼木县| 达州市| 平凉市| 苏州市| 长海县| 廉江市| 资中县| 大名县| 黑龙江省| 体育| 固安县| 厦门市| 辉县市| 德阳市| 龙胜| 临夏县| 阿尔山市| 正蓝旗| 莱州市| 隆化县| 刚察县| 措勤县| 图们市| 浦县| 灵武市| 城口县| 黎平县| 勐海县| 桦川县| 杭州市|